ACN Newswire
Read More

BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine

indie
7 minutes

Vancouver, BC, Nov 11, 2020 - (ACN Newswire) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. Previous interim data from the study showed it possessed an excellent emerging tolerability profile with no noteworthy clinical observations or observed toxicities in the mice. When the study concluded after 6 weeks, the excellent safety and tolerability profile was maintained.The preclinical study, which began in September 2020 and was conducted by leading independent contract research organization ("CRO") Charles River Laboratories, Inc. under contract with BioVaxys, evaluated the anti-virus immune response elicited by BVX-0320 in a controlled murine model by measuring the development of antibodies to the protein that binds the virus to human cells. Following two injections of BVX-0320 together with the immunological adjuvant, QS21, to 28 mice at four dosage levels, 96.4% developed positive antibody responses detected at wee...

SeaPRwire
Read More

US shares end mixed after coronavirus vaccine high fades

elean
3 minutes

NEW YORK (AFP) - Wall Street pulled back from the celebration that followed good news on a potential Covid-19 vaccine, ending Tuesday's (Nov 10) session mixed. The benchmark Dow Jones Industrial Average finished the day with a 0.9 per cent gain at 29,420.92, while the broader S&P 500 dipped 0.1 per cent to 3,545.53. But the tech-heavy Nasdaq lost 1.4 per cent to close at 11,553.86. Optimism about Monday's announcement from Pfizer and BioNTech that their vaccine was 90 percent effective was tempered by the realisation the economic gains likely will not be felt until late next year since it will take months for any vaccine to be widely distributed. Meanwhile, investors are shifting away from the stay-at-home stocks, like videoconference service Zoom, and are returning to back-to-normal shares like airlines and cruise companies. Quincy Krosby from Prudential Financial said "tech names were overbought, reaching the point where we would expect to see some consolidation." That trend should continue as focus turns to "sectors that will benefit from a vaccine once it is distributed and take us to the other side of the pandemic," Krosby said. Uncertainty generated by the US election has rec...

ACN Newswire
Read More

Epazz DeskFlex Desk Scheduling Software Will Release Vaccine Management Solution as Part of COVID Compliance Features

indie
4 minutes

CHICAGO, IL, Nov 10, 2020 - (ACN Newswire) - Epazz Inc. DeskFlex (OTC: EPAZ), a leading provider of mission-critical cloud-computing software solutions, announced today that DeskFlex's vaccine management solution will help organizations plan and develop COVID-19 vaccination programs among its team members when it is released.Pharmaceutical companies are working double-time to create a vaccine against the Novel 2019 Coronavirus. One of the leading pharmaceutical companies, Pfizer, developed a vaccine with a promising result of 90% effectivity according to the company's clinical results. Over 43,538 volunteers participated and received two injections within 21 days apart. The company claimed that among the 94 evaluable COVID-19 cases, results revealed that more than 90% effectively prevented the Coronavirus infection. This result exceeded the Food and Drug Administration set a 50% minimum effectiveness bar. This promising result will pave the way for mass vaccinations if FDA approves the final stage of testing.DeskFlex vaccine management software will facilitate the tracking and management of employees' immunization against the Coronavirus. It allows employees to indicate their vacci...

SeaPRwire
Read More

Singapore could have a Covid-19 vaccine by early 2021; close to $300m commitment from S’pore authorities to make and buy vaccine

aseanpr
4 minutes

SINGAPORE - Singapore could have a Covid-19 vaccine by early next year. The first shipments of the vaccine co-developed by Singapore researchers are expected in the first quarter. Arcturus Therapeutics, the American pharmaceutical company working with Duke-NUS scientists on the vaccine, said this on Monday (Nov 9), as it announced positive preliminary results from the early stage clinical trials ongoing in Singapore. Singapore's Economic Development Board (EDB) is pumping in some US$45 million (S$60.5 million) into the manufacture of the vaccine, said Arcturus. EDB will also have the right to purchase up to $175 million of the vaccine at pre-negotiated prices, with shipments expected to begin in the first quarter of 2021, said Arcturus. Duke-NUS Medical School's Professor Ooi Eng Eong, who had co-developed the vaccine with Arcturus, said the results so far show that the vaccine could be effective as a single dose. "This differentiates this investigational vaccine from many other Covid-19 vaccines in development," said Prof Ooi, who is also a member of Arcturus' Vaccine Platform Scientific Advisory Board. "The vaccine has the potential to provide important public health benefits by ...

SeaPRwire
Read More

Oil soars 8% on promising Covid-19 vaccine results

elean
2 minutes

NEW YORK (REUTERS) - Oil surged about 8 per cent on Monday (Nov 9), putting it on track for its biggest daily gain in more than six months after Pfizer announced promising results for its Covid-19 vaccine, boosting risk assets around the globe. Brent crude was up US$3.11, or 7.9 per cent, at US$42.56 a barrel at 1:35pm EDT (1835 GMT), while US West Texas Intermediate crude rose US$3.31, or 8.9 per cent, to US$40.45. Both contracts rose more than US$4 earlier in the session and traded more than 120 per cent of last session's volumes. "The oil complex is joining in the bullish euphoria of today's optimistic vaccine headlines as well as the weekend election results by trailing the equities higher," said Jim Ritterbusch of Ritterbusch and Associates in Houston. Pfizer said its experimental vaccine was more than 90 per cent effective in preventing Covid-19, based on initial data from a large study, a victory in the battle against a pandemic that has forced lockdowns around the world and led to a drop-off in fuel demand. Wall Street, which oil prices often follow, reached all-time highs after the announcement. Meanwhile, Saudi Arabia said an Opec+ oil output deal could be adjusted to bal...

SeaPRwire
Read More

Morning Briefing: Top stories from The Straits Times on Oct 17

aseanpr
2 minutes

Good morning! Here are our top stories to kick-start your Saturday, Oct 17. Active Covid-19 cases fall below 100 for the first time in Singapore since March 12 30 patients remain in hospital while 59 are recuperating in community facilities. READ MORE HERE Temporary wage cuts: Enduring short-term pain to protect long-term jobs The NWC recommends that employers could cut wages temporarily to minimise retrenchments. READ MORE HERE Thai police pushback against protesters could harden positions Analysts say the Friday crackdown may narrow chances of a political resolution. READ MORE HERE More on this topic Related Story ST newsletters: Get alerts on the latest news Thailand's King Maha Vajiralongkorn says people should love country and monarchy The King's comments were aired as protesters gathered in Bangkok for a third straight day. READ MORE HERE Polls open as New Zealanders decide PM Jacinda Ardern's fate in 'Covid election' Pre-election opinion polls put support for Ms Ardern's party at 46 per cent. READ MORE HERE Singapore and Hong Kong's travel bubble: How Covid-19 rules differ between the cities In Hong Kong, masks do not have to be worn in outdoor public places. READ MORE HERE ...